---
schema_version: "secwatch.filing_event.v1"
accession: "0001159036-23-000004"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2023-01-10T23:59:59+00:00"
generated_at: "2026-06-20T16:52:05.931417+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Halozyme guides FY2023 revenue $815M-$845M, >20% growth; Non-GAAP EPS $2.50-$2.65

## Summary
- FY2023 total revenue guidance $815M-$845M, >20% growth over expected 2022 record revenue >$655M.
- Royalty revenue guided $445M-$455M (>20% growth); EBITDA $415M-$440M (>30% growth).
- Non-GAAP diluted EPS guidance $2.50-$2.65; up to $150M share repurchases under $750M authorization.
- Anticipates two ENHANZE SC launches (efgartigimod, atezolizumab) and four Phase 3 data readouts in 2023.
- Completed Antares Pharma acquisition in 2022; expects continued strength in DARZALEX SC and Phesgo royalties.

## SEC filing metadata
- accession: 0001159036-23-000004
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2023-01-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000115903623000004/0001159036-23-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000115903623000004/halo-20230110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001159036-23-000004
- JSON: https://secwatch.observer/filing/0001159036-23-000004.json
- Plain text: https://secwatch.observer/filing/0001159036-23-000004.txt

## Key facts
- Earnings Releases
  HALOZYME THERAPEUTICS, INC. reported 2023 results: revenue $815 million to $845 million, EPS $2.50 to $2.65. Guidance initiated.
  - Period: 2023
  - Revenue: $815 million to $845 million
  - EPS: $2.50 to $2.65
  - Guidance: initiated
  - Result: guidance update
  source text: Halozyme expects total revenue of $815 million to $845 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1159036/000115903623000004/0001159036-23-000004-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.